Kelly Lawrence W & Associates Inc. CA Invests $554,000 in Edwards Lifesciences Corporation $EW

Kelly Lawrence W & Associates Inc. CA bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, HoldingsChannel reports. The fund bought 6,125 shares of the medical research company’s stock, valued at approximately $554,000.

Several other hedge funds have also modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Edwards Lifesciences in the second quarter valued at $5,318,092,000. State Street Corp grew its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares in the last quarter. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 4.8% during the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares during the period. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $1,274,082,000. Finally, Norges Bank acquired a new position in Edwards Lifesciences in the 4th quarter worth $803,686,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Barclays reiterated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. BTIG Research increased their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Truist Financial raised their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Finally, Mizuho raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 25,570 shares of company stock valued at $2,219,390. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 0.8%

NYSE:EW opened at $90.53 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market capitalization of $52.13 billion, a price-to-earnings ratio of 52.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The stock has a 50-day simple moving average of $89.30 and a 200 day simple moving average of $84.74.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.